key: cord-0854423-3xlhdjan authors: Mahmoudjafari, Zahra; Alexander, Maurice; Roddy, Julianna; Shaw, Ryan; Shigle, Terri Lynn; Timlin, Colleen; Culos, Katie title: American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplant and Cellular Therapy Patients in the United States date: 2020-04-17 journal: Biol Blood Marrow Transplant DOI: 10.1016/j.bbmt.2020.04.005 sha: 63dc434f3fc78955b22f123292b7016ca9c665cb doc_id: 854423 cord_uid: 3xlhdjan Abstract The coronavirus-19 (COVID-19) pandemic poses a significant risk to patients undergoing hematopoietic stem cell transplant or cellular therapy. The American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Steering Committee aims to provide pharmacy practice management recommendations for how to transition clinical hematopoietic stem cell transplant (HCT) or cellular therapy pharmacy services utilizing telemedicine capabilities in the inpatient and outpatient setting to maintain an equivalent level of clinical practice but minimizing viral spread in a high risk, immunocompromised population. Additionally, the Steering Committee offers clinical management recommendations for COVID-19 in HCT and cellular therapy patients based on the rapidly developing literature. As the therapeutic and supportive care interventions for COVID-19 increase, collaboration with clinical pharmacy providers is critical to ensure safe administration in HCT patients. Attention to drug-drug interactions (DDI) and toxicity, particularly QTc prolongation, warrants close cardiac monitoring and potential cessation of concomitant QTc prolonging agents. Expanded indications for hydroxychloroquine and tocilizumab have already shown potential stress to usual supply chain. Detailed prescribing algorithms, decision pathways and specific patient population stock may be necessary. The COVID-19 pandemic has challenged every member of the healthcare team and we must continue to remain vigilant in providing pharmacy clinical services to one of the most high-risk patient populations and remain committed to providing compassionate and safe care for patients receiving HCT and cellular therapies. The COVID-19 pandemic has challenged every member of the healthcare team and we must continue to remain vigilant in providing pharmacy clinical services to one of the most high-risk patient populations and remain committed to providing compassionate and safe care for patients receiving HCT and cellular therapies. On March 11, 2020 the World Health Organization (WHO) declared the new coronavirus, coronavirus-19 (COVID-19) a global pandemic. 1 While the illness is highly contagious it poses a significant risk to immunocompromised patients and patients undergoing hematopoietic stem cell transplant (HCT) or cellular therapy are no exception. There are currently no reports on the outcomes of these patients, however early accounts on the outcomes of patients with cancer infected with COVID-19 indicate a 3.5 times higher risk of ICU admission, mechanical ventilation or dying compared with patients without cancer. 2 As this virus continues to spread throughout the United States many hospitals have worked rapidly to conserve resources and to protect patients in response to the COVID-19 pandemic. Avoiding exposure by adhering to good hygiene practices and social distancing are the only prevention strategies as there are no approved treatment options or available vaccine. 3 Patients with hematologic malignancies receiving HCT or cellular therapy in many cases cannot have their treatment delayed. There are limited recommendations for pharmacist practices working with HCT and cellular therapy patients. We remain a critical and required component of the health care team and must ensure we can continue to monitor patients, provide clinical recommendations and provide critical education to patients in need. 4 The American Society for Transplantation and Cellular Therapy (ASTCT) Pharmacy Special Interest Group (SIG) Steering Committee provides this position statement for pharmacy practice management and clinical management recommendations for COVID-19 in HCT and cellular therapy patients. There have been published reports on managing cancer care during the COVID-19 pandemic and resources are available from both ASTCT and the European Society for Blood and Marrow Transplantation (EBMT) but no reports to our knowledge specifically address pharmacist practice management in the inpatient and outpatient settings and leveraging telemedicine capabilities during these unprecedented cicrumstances. 3, 5, 6 Additionally, many of our institutions include academic learning environments where there are frequently students and pharmacy residents and due to concerns for COVID-19 many changes have been implemented. Consideration should always be given to institutional policies and procedures and practices should be routinely reviewed. Given these unprecedented times, priority should be given to protecting our vulnerable patient population, but also to ensure a safe work environment and protecting the health of the frontline staff. For staff members who must remain at work, policies and procedures should be in place for a strict "stay at home if sick" policy with clear guidelines for when staff can return to work and safely take care of patients. Additionally, facemask guidance and use of personal protective equipment (PPE) should also be outlined within institutional policies and procedures. Despite all initial preparations, flexible and frequent (typically daily) communication to staff is vital to ensure care continuity as this remains a dynamic and quickly evolving situation. Clinical pharmacy services are an established practice within the HCT and cellular therapy team. The ASTCT Pharmacy SIG recommends continued pharmacist monitoring of these high-risk complex patients and access to the health care team for clinical decision-making. The role of the HCT pharmacist is vital for the safety and optimal care of HCT patients and must be maintained for FACT compliance. 4 Depending on the model of inpatient rounds at the institution, our recommendation is to limit exposure to patients and other team members as much as possible. Recognizing the importance of onsite representation of inpatient clinical pharmacy services for urgent and emergent needs, a rotating model working remotely for pharmacists is recommended to limit the number of pharmacists that may be exposed or exposing patients or colleagues. If attending in-person rounds are deemed necessary, we recommend the following: avoid entering patients' rooms if possible, conserve personal protective equipment (PPE), remain 6 feet from other team members, and dress in scrubs that can be routinely laundered. Institution provided scrubs and laundry service could be an ideal resource if available. Modern EMRs and supporting technology allow pharmacists the ability to complete profile review, pharmacokinetic monitoring (e.g. immunosuppression), renal and hepatic adjustments, chemotherapy entry and verification, evaluation of drug-drug interactions and medication reconciliation remotely. Additionally, we recommend consideration be given to standardizing times of medication administration to limit the number of times nurses and respiratory therapists need to enter the patient's room. Consideration should also be given to plan for and mitigate potential drug shortages by identifying potential therapeutic alternatives and if necessary, creating patient selection criteria to conserve supply. Inpatient clinical pharmacy services for HCT and cellular therapy patients should not be negatively impacted or sacrificed despite the need to limit face-to-face patient and caregiver interactions. The outpatient clinic is critical to both acute management and long-term chronic management of the HCT Pharmacists onsite may continue to see patients in clinic if needed, but should identify ways to minimize contact with patients, such as routing information and/or materials through a primary provider that will be interfacing with patients. The modern technologies provided within our institutions can support remote clinical pharmacy services for both the inpatient and outpatient settings and is critical to the successful delivery of care when there is an effort to limit patient contact ( Considering the COVID-19 outbreak, many schools of pharmacy have chosen to cancel in-person classes and favor an online approach. As such, many student clinical rotations have been cancelled or changed to virtual learning. This presents a unique challenge because case-based learning is so beneficial. The ASTCT Pharmacy SIG recommends that if students remain on clinical rotations that the learner work remotely to review patients and provide potential clinical interventions after discussion with their primary preceptor. Patient discussions, recommendations, topic discussions, and other required assignments can be completed with the primary preceptor via platforms such as Zoom® or Skype for Business®. Students may also be assigned to more academic or research type rotations to ensure their exposure to patients is minimized. Regarding current residents, we understand that the COVID-19 pandemic presents a unique challenge, however, we believe that it is in the best interest of the resident to be treated the same as clinical staff. Resident exposure should be limited if possible and therefore they should complete clinical duties remotely when able. Patient monitoring and topic discussion with preceptors can be completed remotely as well. Pharmacy residents may also be requested to assist for other departmental needs such as planning, communication, drug information requests and to aid in staffing. It is ultimately the responsibility of the residency program director to ensure the pharmacy resident continues to meet the goals and objectives outlined to meet requirements for graduation. Novel data supporting potential COVID-19 treatment options are emerging at record pace fueling heavy debate regarding study design and optimal strategies. 3 (Table 2) . For a complete list of DDIs with potential COVID-19 treatments visit http://www.covid19-druginteractions.org/. Chloroquine (CQ) and hydroxychloroquine (HCQ) have garnered significant interest as potential options for treating COVID-19. In-vitro data demonstrates possible viral inhibition by increasing the pH of intracellular lysosomes and endosomes leading to decreased viral membrane fusion. 9 Other mechanisms of viral inhibition involve alterations to glycosylation of ACE2 as well as blocking transport and subsequent release of the viral genome. [9] [10] [11] Pharmacodynamically, both CQ/HCQ are readily bioavailable drugs (~89 and 74%, respectively) with rapid peak concentrations and display multi-compartment pharmacokinetics with significant tissue distribution and long terminal half-lives (30-40 days). [11] [12] [13] [14] They are converted to active metabolites by cytochrome P450 enzymes CYP 3A4, 2D8, and, to a lesser extent, 2D6. Both drugs have also been shown to moderately inhibit CYP 2D6. 15 Based on metabolic pathways, administration with CYP 3A4 or 2D8 inhibitors may result in decreased active CQ/HCQ concentrations and co-administration with 2D6 substrates may increase the concentration of the co-administered drug. There have been two case reports of significantly elevated cyclosporine concentrations when given in combination with CQ but no documented DDI with tacrolimus: suggesting the interaction was not CYP mediated. 16, 17 The frequency, significance, and mechanism for the reported interaction with cyclosporine is unknown and routine pharmacokinetic monitoring is recommended. Regarding administration of either agent, it is recommended to avoid giving antacids within 4 hours to ensure absorption. In patients with compromised oral intake (e.g. mucositis), HCQ cannot be crushed at the bedside and must be compounded to a solution once the external layer is removed. and cellular therapy populations are the overlapping toxicities with concomitant medications. CQ and HCQ are associated with QTc prolongation, especially problematic in HCT patients receiving multiple other QTc prolonging agents such as azole antifungals, fluoroquinolones, macrolides (azithromycin), 5-HT3 antagonists, etc. 19, 20 Electrocardiograms should be obtained prior to starting antiviral therapy with CQ/HCQ. Early reports of dual therapy with HCQ and azithromycin raise considerable concern for QTc prolongation and warrant discussion of risk versus benefit. 7 Vigilant electrolyte repletion is also recommended as HCT patients commonly have significant electrolyte disturbance further increasing their risk of cardiac arrhythmias. A rare but notable adverse effect seen with both agents is alteration in insulin metabolism leading to hypoglycemic events. Patients with concurrent diabetic therapies should be appropriately monitored closely. 21 Other toxicities noted in drug labeling include elevated liver function tests, ophthalmic changes, and glucose-6-phosphate dehydrogenase (G6PD) deficiency-related anemia. Ophthalmic toxicities are typically associated with consistent drug concentration of 6.5 mg/kg/day for >5 years 21 and the G6PD-associated toxicity was not observed in a retrospective review of patients receiving HCQ for autoimmune disease. 23 Given the short course and risk/benefit ratio of initiating COVID-19 directed therapy, these potential toxicities are less concerning however G6PD assessment would be ideal. Remdesivir (GS-5734) is an investigational compound with broad-spectrum antiviral activity. It was first developed during the Ebola outbreak in 2014. 24, 25 Remdesivir is a nucleotide prodrug, which is metabolized to its active nucleoside triphosphate form. It then binds RNA-dependent RNA polymerase, acting as a delayed RNA chain terminator. 26, 27 Remdesivir has demonstrated in-vitro and in-vivo activity in animals first against SARS-CoV-1 and MERS-CoV, and now with potent in-vitro activity against SARS-CoV-2. 28, 29 The current dose being studied is 200 mg IV on day 1, followed by 100 mg IV once daily for 10 days. 30 In the United States, remdesivir is available on clinical trial or via compassionate use; however on March 23, 2020 Gilead Inc. had to temporarily halt use on an individual compassionate basis due to the overwhelming requests. 31 It is still available for pregnant women and children under 18 years of age with severe COVID-19 outside of a clinical trial at this point. Although remdesivir is described as a substrate for CYP2C8, CYP2D6, and CYP3A4 in-vitro, it is thought that inhibitors or inducers of CYP3A4 are unlikely to cause significant drug interactions since remdesivir's metabolism is likely mediated by hydrolase activity. [30] [31] [32] Ribavirin Ribavirin was first discovered in the 1970s and has been used for treatment of hepatitis C, respiratory syncytial virus, and viral hemorrhagic fever. It is a nucleoside inhibitor, which terminates RNA synthesis. 33 Ribavirin, used in combination with other drugs such as corticosteroids or interferon, was utilized as treatment against SARS-CoV-1 and MERS-CoV at very high doses (1.2 gram to 2.4 grams every 8 hours); this was associated with excessive toxicity. [34] [35] [36] It is being studied in combination with interferon and lopinavir/ritonavir against COVID-19. Ribavirin has minimal drug-interactions of note; however, the following may increase the risk for myelosuppression when given in combination with azathioprine, linezolid, and amphotericin B. 32 Lopinovair/Ritonavir The combination of lopinavir and ritonavir, in conjunction with other antiviral agents, is an antiviral regimen currently approved to treat HIV-1. Lopinavir and ritonavir are protease inhibitors co-formulated based on their pharmacokinetic profiles, with ritonavir increasing the plasma half-life of lopinavir via inhibition of cytochrome CYP3A metabolism. 37 Lopinavir/ritonavir is considered a strong CYP3A4 inhibitor and will increase serum levels of CYP3A4 substrates, necessitating dose adjustments or avoidance, depending on the specific drug substrate . Lopinavir/ritonavir was first identified as having antiviral activity against SARS-CoV as both initial and rescue therapy when added to patients treated with ribavirin and steroids. This combination showed a reduction in overall death rate, intubation rate, adverse events (development of ARDS), nosocomial infections and need for rescue pulsed steroids for severe respiratory deterioration. 38, 39 Unfortunately this benefit has not been carried over and reported thus far in patients receiving this therapy for COVID-19. 40 In Tocilizumab Tocilizumab has been utilized as adjunct therapy in COVID-19 patients displaying signs of cytokine release syndrome (CRS). 43 As a monoclonal antibody directed towards the IL-6 receptor it does not undergo any CYP metabolism and is eliminated after bind to the target. 32 patients. An oral JAK1/2 inhibitor, ruxolitinib, is commonly used in the HCT population for the treatment of steroid refractory acute graft versus host disease (GVHD). Its potent immunosuppressive properties also being investigated in COVID-19 with CRS in upcoming Phase III trials. 45 Ruxolitinib is extensively metabolized by CYP3A4 requiring dose adjustment with strong inhibitors/inducers. 46 Dose adjustment for renal dysfunction is also warranted. Myelosuppression and infection are the most common toxicity when used in the setting of GVHD treatment, however, may not be as profound if used for short courses for COVID- The COVID-19 pandemic has challenged every member of the healthcare team. In a short period of time, major restructuring to staffing models has had to occur. Additionally, clinical management of these patients considering the rapidly evolving clinical literature must also remain a top priority. Clinical trials involving other potential treatment options are quickly being designed. We must continue to remain vigilant in providing pharmacy clinical services to one of the most high-risk patient populations and remain committed to providing compassionate and safe care for patients receiving HCT and cellular therapies. World Health Organization Coronavirus Disease 2019 (COVID-19) Situation Report-51 Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China European Society of Blood and Marrow Transplantation Foundation for the Accreditation of Cellular Therapy. Seventh Edition FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing and Administration Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal Interim Guidelines for COVID-19 management in hematopoietic cell transplant and cellular therapy patients COVID-19 Treatment: A Review of Early and Emerging Options, Open Forum Infectious Diseases Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Disposition of chloroquine in man after single intravenous and oral doses A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation Interaction between cyclosporin and chloroquine Drug interaction of chloroquine with ciclosporin Plaquenil prescribing information Accessed 3/24/2020 Aralen prescribing information Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis Hydroxychloroquine: A physiologically based pharmacokinetic model in the context of cancer-related autophagy modulation Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys Controlled Trial of Ebola Virus Disease Therapeutics Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro COVID-19 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases Gilead Halts Remdesivir Access for COVID-19 Amid Other U.S. Drug Shortages Interactions with Experimental COVID-19 Therapies Rebetol (ribavirin) capsules and oral solution Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area A major outbreak of severe acute respiratory syndrome in Hong Kong Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study Coronaviruses and their therapy Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicenter retrospective matched cohort study HKU/UCH SARS Study Group: role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-10 Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Effective Treatment of Severe COVID-19 Patients with Tocilizumab Interleukin-6 and cytochrome-P450, reason for concern? Rheumatol Int Incyte Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm Jakafi (ruxolitinib) [prescribing information Incyte Corporation CQ/HCQ: chloroquine/hydroxychloroquine; RDV: remdesivir; RBV: ribavirin; LPV/r: lopinavir/ritonavir; TCZ: tocilizumab; RUX: ruxolitinib. Arrow depicts effect on immunosuppressant concentration.